Atopic Dermatitis Therapeutics Market statistics and research analysis released in latest report
Date: 2018-09-11   Author: Rahul Sankrityayan  Category: #market

Atopic Dermatitis Therapeutic Market size is projected to experience significant growth from 2018 to 2024.Atopic dermatitis therapeutic market is expected to witness significant growth due to rising cases of Atopic dermatitis with the increase in prevalence of food allergies exacerbating Atopic Dermatitis. Escalation in consumption of chicken eggs, cow’s milk, peanuts, wheat, nuts, soy and fish increase the chances of developing food allergies that result in development of atopic dermatitis. Globally, around one-third of the children with atopic dermatitis are diagnosed with food allergy.

Introduction of the emerging therapies such as baricitinib (Eli Lilly and Company), Tralokinumab (LEO Pharma), Furestem (Kangstem Biotech), and other therapies is expected to fuel market growth in upcoming years. Robust pipeline, advancement in treatment, growing government and pharmaceutical companies’ initiatives for the development of the novel therapies for atopic dermatitis will result in business expansion. Immense need to develop novel therapies for severe recalcitrant patients that do not respond to the existing therapies is the major reason behind extensive molecule in development pipeline.

Factors such as lack of awareness regarding the treatment and diagnosis, patent expiry of marketed drugs, challenges in performing clinical trials, genericization of the existing drugs and poor patient adherence of marketed drugs are hindering the market growth.

Increasing use of conventional systemic immunosuppressants such as azathioprine and cyclosporine that are largely used for the treating moderate to severe patients will boost the product demand. Therefore, systemic immunosuppressants business is expected to witness the significant growth during forecasted period. Approval of novel therapies such as Phosphodiesterase-4 (PDE-4) Inhibitors i.e. Eucrisa (crisaborole) in 2016 and Interleukin Inhibitor-4/ Interleukin Inhibitor-13 (IL-4/IL-13) in 2017 has changed the treatment landscape of atopic dermatitis.

Request In-depth table of contents @ https://www.gminsights.com/request-toc/upcoming/2744

The market for topical route of administration products holds larger market share compared to the oral and injectable products owning to the advantages of topical products such as high patience adherence, cost effectiveness.

U.S. atopic dermatitis market is the largest market in North America as well as in the world’ owing to high prevalence of food and skin allergies, and high prevalence of atopic dermatitis. Also, other factors such as adoption of novel medications, better reimbursement policies and launch of the maximum number of drugs U.S. augment market expansion.

Asia Pacific atopic dermatitis market should grow with an explosive rate due to increasing healthcare expenditure, improving healthcare infrastructure and awareness. Moreover, growing need to address lifestyle induced disorders will play a productive role in introducing atopic dermatitis therapies during the forecast period.

Some of the key industry players include Regeneron Pharmaceuticals Inc, Eli Lilly and Company, LEO Pharma A/S, Glaxosmithkline plc, Novartis AG, Kang Stem Biotech Co., Ltd, Sanofi S.A and others. Among these players, Eli Lilly and Company, LEO Pharma, Kang Stem Biotech Co., Ltd., Glaxosmithkline plc and others are focusing on developing novel therapies for the treatment of Atopic Dermatitis. In January 2018, Regeneron Pharmaceuticals, Inc and Sanofi had accelerated and expanded the investment for the clinical development of the Dupilumab for atopic dermatitis.

Atopic Dermatitis Market by product, 2013-2024 (USD Million)

  • Anti-inflammatory agents
    • Corticosteroids
    • Calcineurin Inhibitors 
  • Antihistamines
  • Interleukin Inhibitors
  • Phosphodiesterase-4 (PDE-4) Inhibitors
  • Antibiotics
  • Immunosuppressants
  • Others

Atopic Dermatitis Market by Route of Administration, 2013-2024 (USD Million)

  • Topical
  • Oral
  • Injectable

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Mexico
  • Middle East and Africa
    • Saudi Arabia
    • South Africa

Company Profiles:

  • Novartis AG
  • Pfizer
  • Connetics Corporation
  • Regeneron Pharmaceuticals Inc.
  • Fujisawa Healthcare
  • Eli Lilly and Company
  • LEO Pharma A/S
  • Kang Stem Biotech Co., Ltd.
  • Glaxosmithkline plc
  • Sanofi S.A
  • Others



About Author


Rahul Sankrityayan

Rahul Sankrityayan

Fortified with a post-graduate degree in Computer Applications, Rahul Sankrityan writes for AlgosOnline, where he pens down news and articles spanning across segments of technology industry that excite him on a day-to-day basis. Rahul comes with a rich experience in t...

Read More

More from Rahul


Post Recommendents

Flat Glass Market Innovative Trends & Growth Forecast Analysis by 2018 to 2024
Author: Rahul Varpe

A significant trend proliferating Flat Glass Market growth lately, is the introduction of green buildings, which constitutes environment friendly and sustainable construction materials. Additionally, intrusion of ...


Waste Heat to Power Market Growth, Business Opportunities by 2024
Author: Rahul Sankrityayan

Waste Heat to Power Market is expected to surpass USD 30 billion by 2024. Growing demand for electricity Increasing concern to reduce the energy bills will stimulate the industry growth. Growing demand...


Europe Anaerobic Digestion Market Trends, Industry Analysis & Forecast by 2024
Author: Rahul Sankrityayan

Europe Anaerobic Digestion Market is expected to surpass USD 8 billion by 2024. Increasing adoption of renewable energy across industrial establishments backed by rapid industrialization will propel in...